We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has lifted clinical holds on studies evaluating Bluebird Bio’s LentiGlobin gene therapy for sickle cell disease (SCD) as well as trials of a treatment for a blood disorder that uses the same viral vector. Read More
Johnson & Johnson (J&J) has decided to call it quits on its global collaboration and licensing agreement with Argenx, an arrangement for a blood cancer drug hashed out in late 2018 that was worth up to $1.6 billion. Read More
Novartis has become the latest pharma company to sue HHS over its threats to levy financial penalties against drugmakers who hold back 340B drug discounts from contract pharmacies, an effort that’s won a preliminary injunction against the fines for now. Read More
Despite an unconvinced advisory committee panel and accusations that the FDA worked too closely with Biogen on its Alzheimer’s drug aducanumab, the agency on Monday moved to OK the drug under accelerated approval in a long-awaited decision for patients with the degenerative neurological illness. Read More
Regeneron Pharmaceuticals has received an updated Emergency Use Authorization (EUA) from the FDA for a lower dosage of its COVID-19 antibody cocktail, REGEN-COV (casirivimab/imdevimab). Read More
AstraZeneca’s (AZ) and Merck’s blockbuster cancer drug Lynparza (olaparib) has made a strong showing in a phase 3 trial evaluating it as an adjuvant treatment for an early form of breast cancer, according to early results from the study. Read More